Etira chosen for Mass Challenge!

Dallas, TX – April 14, 2026

We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of high-impact startups and gives us access to world-class mentors, investors, and healthcare leaders as we advance our clinical trial to more patients and to the next phase!

For us, this is more than recognition — it is acceleration. We’re doubling down on our mission to make a difference in the lives of patients with advanced cancer! Our mission is more than Remission! Grateful to the MassChallenge team for believing in our vision. Grateful to our Dallas biotech innovation group at Pegasus Park!

Program summary: The MassChallenge Healthcare & Life Sciences Traction Program is where validated startups bridge the gap between “promising tech” and a scaling business. Over 10 high-intensity weeks, we help founders achieve the specific milestones that unlock customers, capital, and scale.

Stats: MassChallenge boasts a track record of supporting over 4,500 alumni, who have collectively secured more than $16 billion in funding, and created over 77,000 jobs.